Updates on cardiovascular outcome trials in diabetes

In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardi...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Review Source Type: research

Related Links:

Publication date: Available online 13 August 2018Source: Alzheimer's &DementiaAuthor(s): Anna Marseglia, Laura Fratiglioni, Grégoria Kalpouzos, Rui Wang, Lars Bäckman, Weili XuAbstractIntroductionThe impact of prediabetes and diabetes on cognitive decline and the potential underlying mechanisms remain unclear. We investigated whether prediabetes and diabetes accelerate cognitive decline and brain aging, and the initial pathological changes linked to microvascular processes.MethodsNine-year longitudinal data from the Swedish National Study on Aging and Care-Kungsholmen (n = 2746, age ≥60 years) ...
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
Called Revita, the device is already used for type 2 diabetes because the burning process, ablation, burns off cells which have become resistant to insulin.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
ConclusionsOur data suggest that glucokinase in brain and other non β-cell peripheral hypoglycemia sensors is important in glucose homeostasis, allowing the body to detect and respond to a falling blood glucose.Graphical abstract
Source: Molecular Metabolism - Category: Endocrinology Source Type: research
Older women with osteoporosis who consistently take a bisphosphonate may have a lower risk of fractures and lower total health costs than their counterparts who stop taking these drugs, a U.S. study suggests.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
GI Dynamics has won a nod from FDA to begin a pivotal trial of the embattled EndoBarrier, a technology used to treat patients with type 2 diabetes. The pivotal trial could be a significant turning point in the life of the Lexington, MA-based company, which was founded in 2004. The firm has been approved for staged enrollment with initial approval for treatment of up to 67 study participants including 50 EndoBarrier and about 17 control participants. GI Dynamics said it expects to complete enrollment of Stage I of the study during the first half of 2019. “This IDE approval is the result of more than two ye...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Implants Source Type: news
The combined levothyroxine (T4) and liothyronine (T3) thyroid tablets from Westminster Pharmaceuticals are being recalled to the wholesale level as a precaution because of a risk of adulteration.News Alerts
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
We present one disposable electrochemical test strip with dual enzymatic reaction channel which is capable of simultaneously measuring glucose and blood ketone by one fingertip whole blood drop for clinical identification of diabetic ketosis (DK) and diabetic ketoacidosis (DKA). The blood glucose was measured in the 1st channel while blood ketone was measured in the 2th channel. The proposed test strip fulfils the rigid demand for diabetic patients with DK/DKA without double pricking the finger to determine the blood glucose and blood ketone, respectively. The results of clinical identification of diabetic ketoacidosis by ...
Source: Sensors and Actuators B: Chemical - Category: Chemistry Source Type: research
Conclusion: We consider that if our findings are supported by further studies with larger populations, the measurement of the serum melatonin level may have a future role in the diagnosis and treatment of ED.
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
Harvard Medical School scientists say their new test, giving a 'polygenic risk score', would be the earliest predictor ever. It could be given at birth to spot risk of cancer, heart disease and diabetes.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Conditions:   Diabetes;   Diabetic Foot;   Diabetes Mellitus, Type 2;   Diabetes Mellitus, Type 1 Interventions:   Device: Cytal Wound Matrix 1-Layer;   Other: Standard of Care (SOC) Sponsor:   ACell Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cardiology | Cardiovascular | Diabetes | Endocrinology | Food and Drug Administration (FDA) | Heart